Peripheral Arterial Disease Clinical Trial
— DM PADOfficial title:
Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes
Verified date | January 2024 |
Source | Imperial College London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In the UK there are over 7,000 leg amputations each year because of diabetes. The most important cause of this is poor circulation. The detection of poor circulation in patients with diabetes is difficult. A number of tests exist to detect poor circulation (known as peripheral arterial disease (PAD)). However, there is confusion as to which is the gold standard. The DM PAD study aims to determine the diagnostic performance of index tests (audible handheld Doppler, visual handheld Doppler, ankle brachial pressure index (ABPI), exercise ABPI and toe brachial pressure index (TBPI)) for the diagnosis of PAD in patients with diabetes as determined by a reference test (CTA or MRA).
Status | Active, not recruiting |
Enrollment | 604 |
Est. completion date | February 28, 2024 |
Est. primary completion date | February 28, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Aged =18 years - Known history of diabetes Exclusion Criteria: - PAD status known on imaging - Known history of PAD intervention - CTA and MRA contraindications- renal impairment, pregnancy, contrast medium hypersensitivity/allergy, non-compatible implants (MRA only). - Unable to provide appropriate informed consent. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Mid and South Essex NHS Foundation Trust | Basildon | |
United Kingdom | Cardiff and Vale UHB | Cardiff | |
United Kingdom | University Hospitals of Derby and Burton NHS Foundation Trust | Derby | |
United Kingdom | NHS Greater Glasgow and Clyde | Glasgow | |
United Kingdom | Hull University Teaching Hospitals NHS Trust | Hull | |
United Kingdom | University Hospitals of Leicester NHS Trust | Leicester | |
United Kingdom | Central London Community Healthcare NHS Trust sites | London | |
United Kingdom | Chelsea and Westminster Hospital NHS Foundation Trust | London | |
United Kingdom | Hammersmith and Fulham Partnership | London | |
United Kingdom | Imperial College Healthcare NHS Trust | London | |
United Kingdom | St George's University Hospitals NHS Foundation Trust | London | |
United Kingdom | South Tees Hospitals NHS Foundation Trust | Middlesbrough | |
United Kingdom | Nottingham University Hospitals (NUH) NHS Trust | Nottingham | |
United Kingdom | Oxford University Hospitals NHS Foundation Trust | Oxford | |
United Kingdom | University Hospitals Plymouth NHS Trust | Plymouth | |
United Kingdom | University Hospitals Southampton NHS Foundation Trust | Southampton | |
United Kingdom | Worcestershire Acute Hospitals NHS Trust | Worcester |
Lead Sponsor | Collaborator |
---|---|
Imperial College London | Universidad de Granada, University of Edinburgh, University of Leicester |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic accuracy | Diagnostic accuracy of the PAD-scan and other bedside tests will be compared to the results of a Magnetic resonance angiograph (MRA) or Computed tomography angiography (CTA) (reference test). | 6 weeks; all index tests will be performed on the same day of presentation; reference scan performed within six weeks of the index tests. | |
Secondary | Health economic outcome - cost of test | Cost of the test, including direct costs and amortisation of capital equipment and use of other healthcare resources for prevention and treatment of the disease over a time horizon of 5 years. | 1 hour: all index tests will be performed on the same day of presentation. | |
Secondary | Health economic outcome - Quality Adjusted Life Years | Quality Adjusted Life Years at 5 years | 1 hour: all index tests will be performed on the same day of presentation. | |
Secondary | Health economic outcome - cost effectiveness | Incremental cost-effectiveness ratio at 5 years. | 1 hour: all index tests will be performed on the same day of presentation. | |
Secondary | Specificity of index tests | Comparing index tests to reference tests. | 6 weeks | |
Secondary | Likelihood ratios of index tests | Comparing index tests to reference tests. | 6 weeks | |
Secondary | Predictive values of index tests | Comparing index tests to reference tests. | 6 weeks | |
Secondary | Diagnostic odds ratio of index tests | Comparing index tests to reference tests. | 6 weeks | |
Secondary | Patient acceptability | Patients will be asked to rate their experience of each index test on a Likert scale. | 1 hour: all index tests will be performed on the same day of presentation. | |
Secondary | Technical success | Inability to perform, refusal and discontinuation of tests will be documented | 6 weeks; all index tests will be performed on the same day of presentation; reference scan performed within six weeks of the index tests. | |
Secondary | Inter- and intra-rater reliability | Repeating of index tests by the same and by an alternative operator for the assessment intra- and inter-rater reliability, respectively (only performed in the first 100 volunteering patients). | 6 weeks; all index tests will be performed on the same day of presentation; reference scan performed within six weeks of the index tests. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02022423 -
Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease
|
N/A |